Clinical Trial Update: Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of eribulin mesylate in advanced or recurrent cervical cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Eribulin mesylate (Halaven) (eribulin)

Snippet

Sponsor: University of Southern California | Conditions: Recurrent Cervical Cancer, Stage IIIA Cervical Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-11-06